Replimune REPL
NASDAQ REPL
$15.04 -0.25 (-1.64%)
As of: Sep 4, 2026 · 3:59 PM EDT

Replimune (REPL) Share-based Compensation (2017 - 2026)

Replimune (REPL) posted Share-based Compensation of $8.1 million for Q1 2026, up 15.3% sequentially from $7.0 million in Q4 2025, and down 1.87% YoY from $8.3 million in Q1 2025.

Analysis

Replimune (REPL) Share-based Compensation (2017 - 2026) Analysis & Trends

Replimune has reported Share-based Compensation for 10 years, with the latest figure at $8.1 million in Q1 2026.

  • Quarterly Share-based Compensation fell 1.87% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.3 million (down 7.91% YoY) and the FY2026 annual result came in at $32.3 million, down 7.91% from the prior year.
  • Share-based Compensation rose to $8.1 million in Q1 2026 per REPL's latest filing, from $7.0 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $9.5 million in Q2 2024 and troughed at $5.8 million in Q1 2022.
  • A 5-year average of $8.0 million and a median of $8.2 million in 2023 frame the typical range for Share-based Compensation.
  • The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 66.27% in 2022, then fell 18.43% in 2025.
  • Over 5 years, Share-based Compensation stood at $7.0 million in 2022, then gained by 17.33% to $8.2 million in 2023, then grew by 4.84% to $8.6 million in 2024, then dropped by 18.43% to $7.0 million in 2025, then climbed by 15.3% to $8.1 million in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods registered $8.1 million, $7.0 million, and $8.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 108.10 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 243.00 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 120.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 277.20 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 137.41 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 86.63 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 41.25 Mn
10 Replimune 1.46 Bn 1.46 Bn - 7.67 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 7.67 Mn
Mar 31, 2026 8.13 Mn
Dec 31, 2025 7.05 Mn
Sep 30, 2025 8.34 Mn
Jun 30, 2025 8.76 Mn
Mar 31, 2025 8.28 Mn
Dec 31, 2024 8.64 Mn
Sep 30, 2024 8.65 Mn
Jun 30, 2024 9.48 Mn
Mar 31, 2024 7.92 Mn
Dec 31, 2023 8.24 Mn
Sep 30, 2023 9.12 Mn
Jun 30, 2023 8.85 Mn
Mar 31, 2023 6.92 Mn
Dec 31, 2022 7.02 Mn
Sep 30, 2022 6.99 Mn
Jun 30, 2022 7.19 Mn
Mar 31, 2022 5.77 Mn
Dec 31, 2021 5.92 Mn
Sep 30, 2021 6.31 Mn